Patala

<h3> Absolute Contraindications of Patala </h3> <h4>Pregnancy / Early pregnancy [Risk to developing fetus]</h4> <ul> <li>🛑 <li>Recommendation: Do not use Patala (or isolated lapachol-rich preparations). If you are pregnant or trying to conceive, avoid Patala and consult a physician or qualified Ayurvedic practitioner. <li>Reasoning: The naphthoquinone lapachol-documented in Stereospermum roots-causes high rates of fetal death and severe fetotoxicity in animal models when given during organogenesis; human safety is not established, so use in pregnancy is contraindicated. <li>Scientific_Study_Title: Toxicology of Lapachol in rats: embryolethality. <li>Scientific_Study_Authors: R.R. da Silva, et al. (authors as listed in PubMed entry). <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/11340475/ <li>Scientific_Study_Excerpt: <p>Paraphrased summary from the paper: In controlled experiments lapachol was administered orally to pregnant Wistar rats during the organ-forming period. The treatment produced an extremely high incidence of fetal death and resorptions (reported near-complete fetal mortality at tested doses), while maternal animals showed little overt toxicity. The authors concluded lapachol is strongly embryolethal under the experimental conditions, indicating a potent abortifacient/fetotoxic effect in mammals and supporting a clear contraindication for use during pregnancy.</p> <p>This animal evidence shows a direct, dose-dependent fetal risk; because the same lapachol compound is present in Patala root extracts, standard precaution is to avoid Patala in pregnancy.</p> </ul> <h4>Trying to conceive / Male fertility concerns [May impair male reproductive organs]</h4> <ul> <li>⚠️ <li>Recommendation: People trying to father a child should avoid concentrated Patala/lapachol products and discuss alternatives with a clinician. <li>Reasoning: Short-term lapachol exposure in animal studies produced measurable adverse effects on male reproductive organs (reduced seminal vesicle weight and other reproductive indices), implying reduced male reproductive potential at certain exposures. <li>Scientific_Study_Title: Reproductive toxicity of lapachol in adult male Wistar rats submitted to short-term treatment. <li>Scientific_Study_Authors: (As listed) - e.g., A. (authors per PubMed record). <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/17421057/ <li>Scientific_Study_Excerpt: <p>Paraphrased summary: Adult male Wistar rats given lapachol orally for short durations showed significant reductions in the weight of seminal vesicles and selective effects on reproductive organs. Although standard sperm production measures were not uniformly changed at all timepoints, the findings indicate lapachol can affect accessory sex organs and suggest potential reversible or irreversible impacts on male reproductive physiology depending on dose and duration.</p> <p>Given these findings, lapachol-containing preparations (including Patala extracts standardized to lapachol) are not recommended for men planning conception until safety is clarified clinically.</p> </ul> <h4>Active bleeding disorder or concurrent anticoagulant/antiplatelet therapy [High bleeding risk]</h4> <ul> <li>🩸 <li>Recommendation: Avoid Patala if you are taking warfarin or other anticoagulants, have a bleeding disorder, or are scheduled for surgery-discuss with your prescribing clinician before any use. <li>Reasoning: Lapachol inhibits vitamin K epoxide and quinone reductase enzymes-mechanisms shared with coumarin anticoagulants-potentially potentiating anticoagulant effects and increasing bleeding risk. <li>Scientific_Study_Title: Lapachol inhibition of vitamin K epoxide reductase and vitamin K quinone reductase. <li>Scientific_Study_Authors: Preusch PC, Suttie JW. <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/6497379/ <li>Scientific_Study_Excerpt: <p>Paraphrased summary: In vitro microsomal experiments from rat liver showed lapachol potently inhibits both vitamin K epoxide reductase and the quinone reductase reactions that recycle vitamin K. This biochemical inhibition mirrors the action of coumarin anticoagulants and provides a mechanistic explanation for lapachol’s anticoagulant effects observed in animals and case reports. Inhibition was strain-specific in animals (warfarin-resistant strains were less affected) but the core finding is that lapachol can compromise vitamin K recycling and thus clotting factor activation.</p> <p>Clinically this supports avoiding lapachol-containing herbs (including Patala) in people on anticoagulant/antiplatelet therapy or with bleeding diatheses.</p> </ul> <h4>Known or suspected DNA-damage predisposition / Prior radiation or genotoxic exposures [Genotoxic risk]</h4> <ul> <li>⚠️ <li>Recommendation: Avoid long-term or high-dose Patala/lapachol preparations in people with prior high genotoxic exposure, and seek specialist advice before use. <li>Reasoning: Lapachol showed clastogenic/genotoxic effects in animal assays (micronucleus and chromosomal aberration tests), indicating potential to damage DNA at certain doses-raising concerns for long-term use or use in vulnerable individuals. <li>Scientific_Study_Title: Lapachol induces clastogenic effects in rats. <li>Scientific_Study_Authors: (As listed in PubMed record; see study details). <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/20112181/ <li>Scientific_Study_Excerpt: <p>Paraphrased summary: Male Wistar rats receiving single oral doses of lapachol were assessed for micronucleus formation and chromosomal aberrations in bone marrow cells. The highest tested dose produced a statistically significant increase in micronucleated polychromatic erythrocytes and chromosome aberrations, demonstrating clastogenic activity under the experimental conditions. These findings indicate lapachol can break or rearrange chromosomes in vivo, a hallmark of genotoxic potential.</p> <p>Because Patala contains lapachol, this evidence argues against indiscriminate or long-term high-dose use, particularly in people already at risk from DNA damage (e.g., prior radiotherapy, occupational exposures).</p> </ul> <h3> Relative Contraindications of Patala </h3> <h4>Breastfeeding [Unclear safety - caution advised]</h4> <ul> <li>🤱 <li>Recommendation: Prefer to avoid Patala during breastfeeding because there are no human safety data; if a practitioner recommends it, use minimal/standardized doses only under supervision. <li>Reasoning: No direct clinical studies document safety of lapachol in lactation; given lapachol’s reproductive and systemic effects in animals, transfer into breastmilk and infant exposure cannot be excluded. <li>Scientific_Study_Title: (No direct human lactation study available - evidence is absence/precaution). <li>Scientific_Study_Authors: NA <li>Scientific_Study_Link: NA <li>Scientific_Study_Excerpt: <p>Scientific_Study_Available: NA - no reliable PubMed study specifically documents lapachol or Stereospermum transfer into milk or safety in breastfeeding. Recommendations are therefore precautionary, based on known animal reproductive toxicity of lapachol.</p> </ul> <h4>Use with highly protein-bound drugs [Possible displacement interactions]</h4> <ul> <li>💊 <li>Recommendation: If you take medicines that are highly protein-bound (e.g., some anticonvulsants, anticoagulants, certain antibiotics), consult a clinician before using Patala extracts. <li>Reasoning: Lab studies show lapachol binds human serum albumin at common drug-binding sites; displacement or competition could alter free (active) levels of co-administered drugs, changing efficacy or toxicity. <li>Scientific_Study_Title: Lapachol interacts with human serum albumin: Insights of its impact on the pharmacokinetics of clinically used drugs. <li>Scientific_Study_Authors: (Authors as in PubMed entry). <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/39532172/ <li>Scientific_Study_Excerpt: <p>Paraphrased summary: Biophysical analyses (STD-NMR, ITC, fluorescence) demonstrated lapachol binds to human serum albumin primarily at site I (subdomain IIA) and a secondary site, with appreciable affinity. The study modeled how lapachol could compete with other drugs for albumin binding and thereby affect their free plasma concentrations and pharmacokinetics. While clinical consequences depend on dose and formulation, the biochemical evidence supports caution when combining lapachol-containing products with narrow-therapeutic-index, highly protein-bound drugs.</p> </ul> <h4>Concurrent chemotherapy / DNA-damaging cancer treatments [Potential additive toxicity]</h4> <ul> <li>⚕️ <li>Recommendation: Do not self-administer Patala or lapachol preparations during chemotherapy or radiotherapy without oncology approval. <li>Reasoning: Lapachol/topoisomerase-targeting activity can be cytotoxic to dividing cells; combined use with DNA-damaging cancer therapies could increase toxicity to normal tissues or alter anticancer drug effects. <li>Scientific_Study_Title: Inhibitory effects of lapachol on rat C6 glioma in vitro and in vivo by targeting DNA topoisomerase I and topoisomerase II. <li>Scientific_Study_Authors: (Authors as listed in PubMed). <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/27852319/ <li>Scientific_Study_Excerpt: <p>Paraphrased summary: Lapachol showed dose-dependent inhibition of tumor growth in a rat glioma model and produced DNA damage and apoptosis in cultured tumor cells by inhibiting topoisomerase I and II activities. While this explains potential anticancer effects, it also indicates lapachol is genotoxic to dividing cells-raising the possibility that co-administration with chemotherapy or radiotherapy might increase adverse effects on normal proliferating tissues (e.g., bone marrow, gut epithelium).</p> </ul> <h4>Children and unknown safety in pediatric use [Use only under expert guidance]</h4> <ul> <li>👶 <li>Recommendation: Avoid giving concentrated Patala/lapachol products to children unless prescribed by a pediatric specialist experienced with herbal therapies. <li>Reasoning: Animal toxicology identifies hematological and reproductive adverse findings at higher doses; pediatric safety and dose-response data in humans are lacking. <li>Scientific_Study_Title: Oral toxicology studies with lapachol. <li>Scientific_Study_Authors: (Study record as in PubMed). <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/4989601/ <li>Scientific_Study_Excerpt: <p>Paraphrased summary: Older oral toxicology work across species documented lapachol’s capacity to induce hematological changes (including anemia and alterations in red cell indices), prothrombin time changes and organ effects at certain dose ranges. While species differences exist, these findings underscore the absence of a robust human pediatric safety dataset and argue for cautious, specialist-led use in children.</p> </ul>